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review article
An active placebo is a substance that produces side effects 
similar to an active ingredient while not producing the 
same intended therapeutic effect. The aim of this study is 
to review the literature on the hypothesis of the active pla-
cebo response as a mechanism of action of antidepressants.
It was found that persons who expect the occurrence of 
side effects of a  pure placebo taken under the guise of 
an antidepressant present a  higher degree of depressive 
symptoms than persons who do not expect the occurrence 
of side effects. 
There are reasons to believe that the entirety or part of 
the difference in the effectiveness of antidepressants and 
placebo is due to the fact that participants of the clinical 
trials correctly guess which study group they have been 
assigned to.
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background
Depressive disorder is one of the most common 
mental health disorders. According to the diagnostic 
criteria of the American Psychiatric Association, the 
diagnosis of major depressive disorder requires the 
observation of several signs and symptoms, such as 
low mood, excessive sleepiness or insomnia, weight 
loss, feeling of worthlessness, and unjustified guilt 
(APA, 2013). It is estimated that in the United States, 
depression affects 7.00% of the population annually, 
and persons aged between 18 and 29 years and over 
60 years are particularly vulnerable (see APA, 2013).
According to the dominant hypothesis derived 
from the biological theory of depression, the condi-
tion is associated with abnormal neurotransmission 
in the central nervous system (Beck & Alford, 2009). 
It is suggested that there may be a pathologically in-
creased sensitivity of neurotransmitter receptors in 
the course of depressive disorder. As neurophysiolo-
gists have proven, if the level of a neurotransmitter 
is adequately high, the organism downregulates the 
number of receptors, e.g. serotonin receptors, in or-
der to maintain a  stable neural signal (Stahl, 1994). 
However, if there is a deficiency of a neurotransmit-
ter, it upregulates and increases the number of recep-
tors, e.g. serotonin receptors. It is believed that in de-
pression, the number of serotonin receptors is higher 
due to low serotonin levels. Therefore, if a  person 
suffering from depression and having a  high num-
ber of receptors is given a substance that inhibits the 
reuptake of the neurotransmitter, a new balance of 
neurotransmitters and receptors should be achieved. 
Treatment methods based on the biological theory 
of depression include pharmacotherapy with antide-
pressants. Antidepressants are a heterogeneous group 
of medications and are believed to reduce signs and 
symptoms of depressive disorder (see Rybakowski, 
2011). Antidepressant groups include monoamine 
oxidase inhibitors (MAOIs), tricyclic antidepres-
sants (TCAs), selective serotonin reuptake inhibitors 
(SSRIs), and serotonin-norepinephrine reuptake in-
hibitors (SNRIs). These medications are frequently 
used in clinical practice. In the United States, sales 
growth of pharmacological agents, particularly anti-
depressants, is observed (Gu, Dillon, & Burt, 2011).
The aim of this study is to review the hypothesis 
of the active placebo response as a mechanism of ac-
tion of antidepressants. 
active placebo response 
hypothesis
The biological theory is criticized, as the main evi-
dence supporting this theory is the claimed effec-
tiveness of antidepressants in the treatment of de-
pressive disorders, as well as ambiguous results of 
experimental studies on the effect of the medications 
on the receptor activity in the central nervous sys-
tem (Cowen, 2008). It has been suggested that em-
pirical evidence confirming the chemical imbalance 
theory is insufficient, however, it seems not to have 
affected its popularity (Lacasse & Leo, 2015). In one 
of the most interesting studies, mice that were unable 
to produce serotonin were bred in order to investi-
gate whether they would display depressive symp-
toms (Angoa-Pérez et al., 2014). The mice displayed 
compulsive and aggressive behaviors, but no signs of 
depression were observed. Moreover, when the mice 
were subjected to stress, there was no difference in 
behavior of normal mice and mice without serotonin 
receptors. The researchers concluded that serotonin 
cannot be the main factor contributing to the etiol-
ogy or development of depressive disorder.
It should be noted that an alternative mechanism 
of action of antidepressants has been presented, and 
it does not refer to the chemical imbalance theory – 
the active placebo response hypothesis (Kirsch, 2009; 
see Siwak, Oronowicz-Jaśkowiak, & Oronowicz-
Jaśkowiak, 2017). Selected publications suggest that 
the effect of antidepressant treatment is indeed the 
same as the active placebo response, which takes 
place when the patient experiences side effects of 
taken medications (Kirsch, 2014). It is underlined that 
antidepressants cause a number of easily noticeable 
side effects, such as dry mouth (xerostomia), drowsi-
ness, anxiety, and low libido (e.g., Hughes, Lacasse, 
Fuller, & Paulding-Givens, 2017). It is suggested that 
if a patient discovers one of these side effects, they 
conclude that they are in the study group receiving 
the active substance, and not the placebo (Rabkin 
et al., 1986), which affects their expectations of the 
effectiveness of the treatment. 
When defining the term active placebo, it can be 
assumed that it is an agent that does not contain any 
active ingredient (in this case, an antidepressant), but 
produces similar side effects as the active treatment 
(active ingredient of antidepressants) (Bąbel, 2006; 
Dolińska, 2011).
It is also noted that in clinical trials, the awareness 
of the fact that the participant may receive a placebo 
instead of a real medication is related to the percent-
age of patients that respond to treatment. The per-
centage of patients responding to treatment when 
(1) the subjects are aware of the fact that there is no 
possibility that they are in a group receiving a pure 
placebo instead of a medication, and (2) the subjects 
are aware of the fact that there is a possibility that 
they are receiving either a medication or a pure place-
bo was 60.00% and 46.00%, respectively (Sneed et al., 
2008). Recent experimental studies have shown that 
the therapeutic effect of selective serotonin reuptake 
inhibitors (escitalopram was used in the study) was 
two to three times higher (in terms of the reduction 
of signs and symptoms of depressive disorder or so-
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cial anxiety) when the patient was sure that they had 
received an active substance than when the patient 
was not sure whether they had been administered an 
antidepressant or a placebo (Faria et al., 2017). In ad-
dition, the study revealed that these two groups of 
patients were characterized by a different neural re-
sponse of brain areas responsible for the interaction 
of cognitive and emotional processes (Faria et al., 
2017). Other studies have shown that patients’ expec-
tations towards therapy have a significant influence 
on their depressive signs and symptoms (Rutherford 
et al., 2016).
The above described observations affect the out-
comes of pharmacotherapy. It is reported that the 
higher effectiveness of active medications when com-
pared with placebo is not caused exclusively by the 
suggested chemical mechanism of action of a medi-
cation. This leads to overestimating the effectiveness 
of pharmacotherapy (Lund, Vase, Petersen, Jensen, 
& Finnerup, 2014; Kube & Rief, 2017). The interfering 
factors include, among others, the conditioning pro-
cess and expectations towards effectiveness of treat-
ment (Kube & Rief, 2017).
direct evidence supporting 
the active placebo response 
hypothesis as a mechanism  
of action of antidepressants
The first scientific report that showed a  clear rela-
tionship of the placebo response with the efficacy 
of antidepressant therapy was a  meta-analysis of 
19 clinical trials: Listening to Prozac but hearing pla-
cebo (Kirsch & Sapirstein, 1998). This meta-analysis 
revealed a 0.90 correlation between the therapeutic 
effect of antidepressant treatment and the placebo 
response in the control group. The meta-analysis 
reported that antidepressants and psychotherapy 
all reduced depressive signs and symptoms, but the 
therapeutic effect of fluoxetine was stronger than the 
placebo response.
It must be noted that conclusions of the study by 
Kirsch and Sapirstein (1998) were criticized, as the 
method for analyzing the results that was used by 
the authors could result in artifacts related to the re-
gression to the average due to comparing two groups 
with a high intensity of the examined feature (Dawes, 
1998). Further criticism was also presented by Klein 
(1998), but at least some of Klein’s objections regard-
ing Kirsch’s “irrelevant speculations” may not re-
main true today. Subsequent studies have extended 
the research perspective by using active placebo and 
different groups of patients.
A meta-analysis of 131 clinical trials that com-
pared the therapeutic effect of selective serotonin 
reuptake inhibitors with pure placebo indicated that 
antidepressants show higher effectiveness than pure 
placebo; however, the difference was established to 
be too small to be clinically relevant (Jakobsen et al., 
2017). The mean improvement difference between 
the groups was 1.94 on the Hamilton Depression 
Rating Scale, while the difference that is expected for 
a  therapeutic method to be recognized as effective 
should be at least 3 points (Jakobsen et al., 2017).
A meta-analysis of 9 clinical trials in which active 
placebo was used indicated that antidepressant treat-
ment is slightly more effective than the administra-
tion of active placebo (d = 0.39) or that the difference 
between the groups is not significant, depending on 
the data analysis approach – liberal or conservative 
(Moncrieff, Wessely, &  Hardy, 2004). On the other 
hand, another meta-analysis suggests that the lack of 
difference between active placebo and antidepressants 
may depend on a particular substance (Hieronymus, 
Lisinski, Nilsson, & Eriksson, 2017). It has been ob-
served that patients taking paroxetine and experienc-
ing side effects had the biggest clinical improvement 
(when compared with patients taking pure placebo 
and patients taking paroxetine and not experiencing 
side effects); however, in the case of citalopram, the 
outcomes were similar for taking citalopram and ex-
periencing side effects and taking citalopram and not 
experiencing side effects, and the difference between 
groups was not significant (p = .140). 
Greenberg et al. (1994) observed a significant cor-
relation between symptom reduction and side effects 
of selective serotonin reuptake inhibitors. Impor-
tantly, the correlation applied both to signs observed 
by clinicians (r = .85) and to symptoms reported by 
patients (r = .96).
The above described studies may support the hy-
pothesis of the active placebo response as a  mech-
anism of action of antidepressants. However, it 
should be kept in mind that there are significantly 
fewer studies that use an active placebo than studies 
that use a pure placebo (Jensen, Bielefeldt, & Hrób-
jartsson, 2017). Nevertheless, there is also indirect 
evidence supporting the hypothesis of the active 
placebo response as a mechanism of action of antide-
pressants, as will be shown in the next section.
indirect evidence supporting 
the active placebo response 
hypothesis as a mechanism  
of action of antidepressants
It is believed that many pharmacological agents help 
reduce the severity of depression. These medications 
include, among others, psilocybin (Dydak, Sliwin-
ska-Mosson, &  Milnerowicz, 2016), carbamazepine 
(Zhang et al., 2008), and, in combination with anti-
depressants: benzodiazepines (Furukawa, Streiner, 
Young, &  Kinoshita, 2001), thyroid hormones (Ar-
onson, Offman, Joffe, &  Naylor, 1996), risperidone 
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(Ostroff &  Nelson, 1999), and lithium compounds 
(Bauer & Döpfmer, 1999). In addition, supplementing 
omega-3 fatty acids is believed to reduce depression 
(Osher &  Belmaker, 2009). The evidence for the ef-
fectiveness of these medications, which are supposed 
to act independently from the chemical imbalance 
theory, may support the hypothesis that pharma-
cological treatment of depression is not specific for 
antidepressants.
It should also be noted that empirically supported 
methods of depression treatment are not limited to 
pharmacological agents (e.g., Rybakowski, 2011), but 
also include physical activity (Netz, 2017), cognitive-
behavioral psychotherapy (Hofmann et al., 2012), 
mindfulness meditation (Ramel, Goldin, Carmona, 
& McQuaid, 2004), short-term psychodynamic ther-
apy (Driessen et al., 2010), and eye movement desen-
sitization and reprocessing (Edmond, Rubin, & Wam-
bach, 1999; Capezzani et al., 2013). It must be noted 
that these methods are supposed to have various 
mechanisms of action and their characteristics differ. 
However, their non-specific effects enable depressive 
symptoms to be improved.
Some of the most interesting studies focus on the 
effectiveness of homeopathy, which, similarly to pla-
cebo administration, does not introduce active sub-
stances to the patient’s organism (NHMRC, 2015). 
The results of a  study with 566 patients, some of 
whom consulted a homeopath, suggest that homeop-
athy is equally effective as antidepressants in reduc-
ing depressive symptoms (measured with the PHQ-9 
questionnaire) (Viksveen, Relton, & Nicholl, 2017). In-
terestingly, the duration of the study was 12 months, 
which is unusually long for this kind of research.
Herbal preparations are also used in treatment or 
supportive treatment of major depressive episodes or 
affective disorders that are not classified as major de-
pression, Hypericum (St. John’s wort) being a notable 
example. Hypericum is believed to improve reuptake 
of serotonin, noradrenaline and dopamine (Koszew-
ska, 2003). However, it must be noted that there is 
no reliable evidence to support the use of St. John’s 
wort for depressive disorder. A study on 340 patients 
diagnosed with depression based on DSM-IV criteria 
was conducted (Hypericum Depression Trial Study 
Group, 2002). The patients were divided into groups 
taking an antidepressant (Serotax), placebo or Hyper-
icum. After 8 weeks and 6 months of treatment, there 
was no difference in the outcome between groups. In 
other words, antidepressant, placebo, and Hypericum 
were all equally ineffective. 
A meta-analysis on depression treatment with Hy-
pericum indicated that it presents a therapeutic effect 
greater than placebo and similar to antidepressants 
(studies included fluoxetine, sertraline, imipramine, 
citalopram, paroxetine, maprotiline, and amitripty-
line; Ernst, 1995). Interestingly, the authors of another 
meta-analysis comparing the effectiveness of Hyperi-
cum and placebo observed that Ernst’s conclusions 
were essentially true, but only in the case of German 
patients (Linde, Berner, & Kriston, 2008). The analy-
sis of the participants’ nationality revealed that 8 out 
of 11 German clinical trials reported Hypericum to be 
more effective than placebo, whereas none of the non-
German studies found Hypericum to be effective. The 
combined effectiveness of Hypericum and placebo was 
significantly higher in German-speaking countries. 
The results of the analysis may show the role of differ-
ent cultural expectations and its effect on the clinical 
outcomes or may indicate a different methodological 
approach of German researchers. On the other hand, 
the observed difference may be due to differences in 
the quality of products distributed in Germany and in 
other countries, resulting from using different brands 
containing varying doses of the supplement (see Kle- 
mow et al., 2004). In Germany, there are regulations 
concerning, among others, the amount of active in-
gredient in Hypericum supplements.
Particular attention should be drawn to the use 
of antidepressants in minor depressive disorder (i.e. 
mild, short-term depression). A meta-analysis of 
6 clinical trials on the effectiveness of fluoxetine, am-
itriptyline and isocarboxazid in treatment of minor 
depression (Barbui, Cipriani, Patel, Ayuso-Mateos, 
& van Ommeren, 2011) showed that treatment with 
these substances is no more effective than placebo. 
Moreover, according to the guidelines of the National 
Institute for Health and Care Excellence (NICE, 2009), 
antidepressants should not be used for treatment of 
mild and short-term depression, as their effective-
ness compared with placebo is hard to demonstrate. 
Nevertheless, the Institute underlines that antide-
pressants may be indicated in treatment of dysthy-
mia and other forms of mild, long-term depression. 
It is also suggested that previous analyses prov-
ing the effectiveness of antidepressants are burdened 
with a high risk of error due to the controversies ac-
companying clinical trials that they were based on 
(Deacon & Spielmans, 2017). The re-analysis of the ef-
fects of treatment of major depressive disorders of ad-
olescents with paroxetine and imipramine may serve 
as an example (Le Noury et al., 2015). The re-analysis 
of the clinical data was performed by a  team other 
than the team responsible for the primary analysis, 
which was sponsored by GSK Pharmaceuticals. It was 
proven that the interpretation method of clinical data 
that supported the use of paroxetine and imipramine 
in treatment of major depressive disorder in adoles-
cents was faulty. In the paper by Keller et al. (2001), 
the endpoint of the study was modified after the trial 
had been completed. According to the standards for 
conducting clinical trials, the endpoint should be es-
tablished before the onset of the trial to determine 
what would be considered a significant improvement 
in the patients’ condition. In this case, without modi-
fying primary data, the final conclusion changed – it 
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was concluded that paroxetine was an effective drug, 
whereas the same data with the previous endpoint 
would have proven otherwise. It was later shown that 
paroxetine and imipramine were equally effective as 
pure placebo (Le Noury et al., 2015). Le Noury et al. 
(2015) also underlined the need for a  greater trans-
parency of clinical trial databases. GSK Pharmaceu-
ticals received a major fine for marketing paroxetine 
as a safe drug for the treatment of major depressive 
disorder in adolescents (Reuters, 2015).
An analysis of the results of clinical trials on an-
tidepressants from the years 1987-2013 was conduct-
ed in order to determine whether the differences in 
clinical outcome between placebo and antidepres-
sants varies over time (Khan, Fahl Mar, Faucett, Khan 
Schilling, & Brown, 2017). This study was a response 
to a publication cycle suggesting that over time, the 
therapeutic effect of antidepressant increases, but this 
effect was to depend exclusively on the increasing 
share of the placebo effect in its efficacy. It was prov-
en that over time, the positive outcomes of both anti-
depressants and placebo increase to the same extent. 
In this analysis, the aspect of expecting certain side 
effects of taking placebo or medication was not dis-
cussed, as the analyzed studies did not report on side 
effects perceived by the patients. It is possible that if 
the aspect was controlled, the difference between the 
placebo effect and the active substance effect would 
increase over timeOn the other hand, Huneke et al. 
(2017) published an interesting experimental study, in 
which the relationship between emotional process-
ing and taking a  placebo was examined. Emotional 
processing is believed to be an adequate new index 
for testing antidepressant effectiveness. The partici-
pants were randomized to one of three study groups 
(placebo, antidepressant, no treatment) and were as-
sessed using psychological tools evaluating emotional 
processing. There was no difference between the pure 
placebo group and the no treatment group in emo-
tional processing. In this study, the occurrence of 
side effects was not controlled, and the authors are 
yet to present a detailed comparison of the three ex-
perimental groups and only compared placebo and 
no treatment groups. The results seem to contradict 
what we know about placebo, and it would be very 
interesting to see a similar study on an active placebo. 
If an active placebo affected emotional processing to 
a greater extent than a pure placebo, it would be an-
other argument for using an active rather than a pure 
placebo in control groups. 
conclusion and further 
directions
The arguments for the active placebo response hypoth-
esis are based on direct and indirect evidence. Direct 
evidence includes a  smaller number of experimental 
studies in which an active placebo was used which re-
port no significant difference in outcomes of treatment 
with antidepressants and an active placebo. Moreover, 
it may be assumed that the reduction in depressive 
signs and symptoms can be achieved by a variety of 
pharmacological agents (including medications other 
than antidepressants), as well as by different non-
pharmacological treatment methods. It seems that 
a common factor of all these methods is patients’ or 
participants’ conviction of their effectiveness. 
It is important to conduct experimental studies in 
which researchers manipulate participants’ expecta-
tions on the occurrence of side effects when taking 
antidepressants. The majority of currently avail-
able studies did not include an active placebo – only 
antidepressants and pure placebos were tested, and 
additional questionnaires were distributed in order 
to collect information on side effects that the partici-
pants had experienced during the trial. The aware-
ness of the fact that when taking part in a  clinical 
trial, one may be included either in a group receiv-
ing placebo or receiving a  medication, may not be 
neutral to the treatment outcomes due to patients’ 
different expectations. 
It is necessary to study the frequency of patients 
discovering their study group assignment. According 
to the active placebo response theory, participants of 
studies guess their study group after having observed 
some side effects. The assumption is important for 
the theory; however, empirical studies are scarce.
Although the Hamilton Rating Scale for Depres-
sion (Hamilton, 1986), which can be considered a valu-
able diagnostic tool (Kirsch, 2009), has been frequently 
used in drug efficacy studies, it seems appropriate 
to test the hypothesis with other depression scales. 
It cannot be doubted that the Hamilton Rating Scale 
for Depression is an adequate tool for measuring de-
pressive signs and symptoms, as it is characterized by 
good psychometric properties, and the evaluation is 
performed by a clinician who assesses the symptoms 
by observing the patient (Gençöz, Gençöz, & Soykan, 
2007). However, the inclusion of more tools could thus 
support the ecological validity of the active placebo 
response hypothesis. Furthermore, it has been proven 
that self-rated scales might be more sensitive than 
clinician-rated scales in milder forms of depression 
(Cuijpers, Li, Hofmann, & Andersson, 2010).
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